By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Daiichi Sankyo Company, Ltd. 

3-5-1, Nihonbashi-honcho

Chuo-ku  Tokyo  103-8426  Japan
Phone: +81-3-6225-1111 Fax:


SEARCH JOBS

Daiichi Sankyo is focused on the discovery and development of novel oncology agents with the goal of delivering first-in-class and best-in-class treatments that address unmet medical needs. The oncology pipeline of Daiichi Sankyo continues to grow and currently includes both small molecules and monoclonal antibodies with novel targets in both solid and hematological cancers.

YEAR FOUNDED:

1899

LEADERSHIP:

CEO: Joji Nakayama

CLINICAL TRIAL:

Please click here for clinical trial information.

PRODUCTS:

All Products


Key Statistics


Email:
Ownership: Private

Web Site: Daiichi Sankyo
Employees:
Symbol: 
 



Industry
Pharmaceutical






Company News
Daiichi Sankyo Announces New Subgroup Analyses Of Once-Daily SAVAYSA (Edoxaban) In Patients With Non-Valvular Atrial Fibrillation To Be Presented At AHA Scientific Sessions 2016 11/7/2016 10:07:49 AM
Portola (PTLA) Expands Clinical Collaboration Agreement With Daiichi Sankyo Worth Up To $25 Million To Develop Andexxa (Andexanet Alfa) In Germany 11/1/2016 10:49:57 AM
Daiichi Sankyo Release: Anti-HER3 Monoclonal Antibody Patritumab Selected For I-SPY 2 TRIAL In Breast Cancer 10/25/2016 8:43:49 AM
Daiichi Sankyo And Inspirion Delivery Sciences Announce U.S. Licensing Agreement For MorphaBond Formulated With SentryBond Abuse-Deterrent Technology 10/25/2016 7:42:57 AM
Daiichi Sankyo and Plexxikon Suspend Phase III Trial of Drug for Rare Tendon Cancer 10/19/2016 5:47:33 AM
Daiichi Sankyo And Dana-Farber Cancer Institute Announce Lung Cancer Research Collaboration 10/12/2016 7:24:39 AM
Daiichi Sankyo Announces First Patient Enrolled In Phase 3 QuANTUM-First Trial Investigating Quizartinib In Newly-Diagnosed FLT3-ITD+ Acute Myeloid Leukemia 10/11/2016 6:49:50 AM
Daiichi Sankyo Presents Late-Breaking Phase 1 Data For Novel Investigational HER2-Targeting Antibody Drug Conjugate DS-8201a In T-DM1 Pre-Treated Breast Cancer At The ESMO 2016 Congress 10/10/2016 7:24:55 AM
Daiichi Sankyo Announces New Strategic Immuno-Oncology Research Collaboration With AgonOx 10/4/2016 6:40:45 AM
Zymeworks And Daiichi Sankyo Announce Immuno-Oncology Cross-Licensing Agreement And Bi-Specific Antibody Collaboration 9/28/2016 8:10:51 AM
12345
//-->